Hepatocellular carcinoma is one of the deadliest cancers in the world. In this study, a hepatocarcinoma-specific binding peptide, which could be used for drug delivery in targeting therapy, was obtained by in vivo phage display technology. After three rounds of panning, only the potential motif Pro-Ser was found in 80 sequenced phage clones. Phage A54 (sequence AGKGTPSLETTP) was shown to be the most effective and specific to the liver cancer cells by cell-based ELISA in all 130 tested clones. After phage A54 was injected i.v. into the xenograft-bearing mice for in vivo distribution, phage enrichment was found in tumor tissues compared with control phage C10 and normal liver tissues through phage titering and immunohistochemical staining. Next, the specific binding ability of synthesized peptide A54 was further confirmed by fluorescence microscopy, competition binding, and fluorescence-activated cell sorting assay. A54 and A54M (sequence AGKGTAALETTP) were synthesized and coupled to doxorubicin (DOX) to do the preliminary targeting therapy. After the treatment, the proliferation of liver cancer cells treated with A54-DOX was restrained significantly in vitro when compared with A54M-DOX-treated group. Reduction in tumor size and prolongation of long-term survival were also found in xenograft-bearing models compared with free DOX-treated group. In conclusion, the specific binding peptide A54, which was screened from phage display library, represents a promising approach for the development of novel target therapy strategies against hepatocellular carcinoma. Mol Cancer Res; 8(2); 135-44. ©2010 AACR.
Introduction
Hepatocarcinoma is one of the most challenging malignancies with a very high mortality (1, 2) . Despite therapeutic advances, the treatment to patients with hepatocellular carcinoma (HCC) still falls short of effectivity or credibility (3) . In the last 2 decades, a new therapeutic modality directed against tumor molecular targets, defined as "targeted therapy," has been developed rapidly (4) . Through the Human Genome Project (5, 6), many proteins have been identified as liver tumor molecular markers, such as α-fetoproteins, melanoma-associated antigens, and matrix metalloproteinases (7) . Some of them have already been developed as molecular targets for cancer diagnosis and therapeutics. However, the current diagnostic accuracy and therapy efficacy for hepatocarcinoma are still far from satisfactory. Therefore, there is a great need to identify some new hepatocarcinoma-specific markers for more precise diagnosis and efficacious therapy of liver cancer.
Phage display is a molecular diversity technology that allows the presentation of a large number of peptides or proteins on the surface of filamentous phages for various applications. These libraries permit the selection of peptides or proteins with high affinity and specificity on almost any target. The most important feature of this technology is the direct link between the experimental phenotype and its encapsulated genotype (8) . Since 1985 (9) , phage display has been an important tool for both basic research and drug discovery. It has provided a rich source of applications from the detection of protein-protein interactions to molecular evolution. Direct selection of markers inside a living organism (termed in vivo panning) is one of the most effective approaches available to date to investigate cellular and vascular heterogeneity. Compared with traditional molecular or cell-based panning strategy, in vivo panning was done under natural environment. So it is possible to explore unknown targets or markers of given tissues in mouse model even in a human subject (10) . In the past few years, this technology has been used successfully for screening ligands to vascular endothelium (11) in different tumor models, such as lung cancer (12) , prostate (13) , and HCC (14) . As several peptides derived by in vivo panning technology have been developed into clinical trials, the use of in vivo phage display to identify cancer, especially vascular heterogeneity targeting therapeutics, should be further exploited (15) .
In the present study, we used in vivo phage display technology to identify peptides that can specifically bind to several human HCC cell lines, such as BEL-7402, BEL-7404, SMMC-7721, and HepG2, in vitro and even BEL-7402 xenograft-bearing models in vivo. After A54 has been coupled to doxorubicin (DOX) for in vivo target therapy, the growth of the tumors was inhibited and the lifetime of the mouse was prolonged when compared with the untreated and DOX-treated groups. Meanwhile, if we mutated the potential motif Pro-Ser in A54-DOX to Ala-Ala (A54M-DOX), the specific cytotoxicity to liver cancer cells of A54-DOX was lost. Our results have shown the possibility to identify tumor-specific targeting peptides by in vivo panning strategy. In fact, one of our selected peptides, A54, has been proven to have great potential in hepatocarcinomatargeting therapy.
Materials and Methods

Materials
The nude mice were purchased from the Shanghai Laboratory Animal Center. All animals were kept under specific pathogen-free conditions and tended in accordance with institutional guidelines. The HCC cell lines BEL-7402, BEL-7404, SMMC-7721, and HepG2; normal liver cell line HL-7702; and other control cell lines were all purchased from the cell bank of Shanghai Institute for Biological Sciences (Shanghai, China). The 12-mer PhD Phagedisplayed Peptide Library was purchased from New England BioLabs. FCS and RPMI 1640 were purchased from Invitrogen. Peptides A54 (AGKGTPSLETTP), A54M (AGKGTAALETTP), and C10 (HSYHSHSLLRMF) were synthesized and conjugated to 6-carboxy-fluorescein (FAM; excitation, 490 nm; emission, 520 nm) or DOX by ChinaPeptides Co. Ltd. Phage DNA isolation and sequencing was done by shDNA Biosciences Ltd. Horseradish peroxidaseconjugated sheep anti-rabbit immunoglobulin was purchased from Sigma Chemical. Rabbit anti-M13 bacteriophage antibody was kindly provided by Dr. Lin-Fa Wang (Commonwealth Scientific and Industrial Research Organisation, Australian Animal Health Laboratory, Geelong, Victoria, Australia).
In vivo Panning
Tumor was raised by s.c. injection of 1 × 10 6 BEL-7402 cells per mouse in 200 μL culture medium with 10% FCS into the flanks of the nude mice. When tumors reached a size of ∼1 cm 3 , phage library containing 10 11 colony-forming units (CFU) was injected through the tail veins of the mouse. After 15 min, mice were sacrificed (three mice were used for panning and one for negative control) and perfused through heart with 100 mL of D-Hank's buffer. Tissue aliquots from tumor, lungs, liver, kidneys, and brain were then collected, minced, and suspended in 2 mL DHank's buffer for phage titering or immunohistochemical analysis. For the amplification of the remaining phages, the remaining tumor tissue was minced and mixed with 20 mL of Escherichia coli ER2738 culture (at early-log stage) and incubated at 37°C with vigorous shaking for 4.5 h. Then, the amplified phages were purified and titered for the next round of panning. After the third round of panning, the phages were picked out randomly for DNA sequencing and homologous analysis.
Phage Binding Assay Using Cell-Based ELISA BEL-7402 and control cell line HL-7702 were cultured in RPMI 1640 with 10% FCS at 37°C in a humidified atmosphere containing 5% CO 2 . The cells were digested with 0.25% trypsin, suspended in serum-containing medium to 10 5 /mL, and added into 96-well plate (100 μL/well) the day before use. Cells were washed, incubated in serumfree medium at 37°C for 1 h, and then fixed in 4% paraformaldehyde in PBS for 20 min. Cells were washed thrice with PBST-05 (PBS with 0.05% Tween 20) and blocked with blocking buffer (PBST-05 contained 3% bovine serum albumin) at 37°C for 1 h. Each selected phage clone was added to the cells at 10 10 CFU per well, and the plate was incubated at 37°C for 1 h. Subsequently, unbounded phages were removed by washing the plate thrice with PBST-05. To detect the bound phages, each well was incubated with 100 μL of rabbit anti-M13 antibody (diluted 1:5,000 with blocking buffer) for 1 h at 37°C. These wells were washed thrice with PBST-05 and subsequently incubated with 100 μL of horseradish peroxidase-conjugated sheep anti-rabbit immunoglobulin (diluted 1:2,000 with blocking buffer). Subsequently, color development was carried out to each well by adding 100 μL of freshly prepared substrate solution [1 mg/mL o-phenylenediamine (Amresco, Inc.) in 0.1 mol/L citrate buffer (pH 4.2) containing 0.03% H 2 O 2 ] and incubating the plate for 20 min at room temperature. The absorbance (490 nm) was then determined on a PowerWave XS Microplate spectrophotometer (Bio-Tek; ref. 16) . Selectivity is determined using the following formula:
Here, OD S1 and OD C1 represent the values of the binding to BEL-7402 cells by the selected phage and control phage, respectively; OD S2 and OD C2 represent the values of the binding to control cell line HL-7702 by the selected phage and control phage, respectively.
In vivo Binding Assay
Phage A54 and irrelevant control phage C10 (10 12 CFU) were injected i.v. into tumor-bearing nude mice as described previously for the initial panning. After 15 min of circulation in the nude mouse, tumor and normal control tissues were collected to determine the phage amount in tissues. For immunohistochemical analysis, tissues were recovered, sectioned (5 μm thick) in cryostat (Leica CM 1850) at −20°C, mounted on poly-L-lysine-coated glass microslides, and fixed in ice-cold acetone for 10 min for immunohistochemical staining. After washing the slides thrice with PBST-05, endogenous peroxidase was blocked by incubating the slides in methanol containing 0.75% (v/v) H 2 O 2 . The slides were washed thrice (5 min for each wash) in PBST-05 and incubated with blocking buffer (3% bovine serum albumin in PBST-05) for 30 min at 37°C and then for 1 h at room temperature in a moist chamber. Subsequently, slides were incubated overnight at 4°C with rabbit anti-M13 antibody (diluted 1:750 in blocking buffer). On the following day, slides were rinsed thrice (10 min for each rinse) in PBST-05 and incubated with horseradish peroxidase-conjugated sheep anti-rabbit immunoglobulin (diluted 1:500 in blocking buffer) for 1 h at room temperature. Afterwards, the slides were rinsed thrice (5 min for each rinse) in PBST-05. The bound phages were visualized using 3,3′-diaminobenzidine (Sigma Chemical) in PBS (pH 7.6) containing 0.03% H 2 O 2 . Finally, when the staining of bound phages was evident, slides were rinsed for 10 min in running tap water before dehydration and mounting for observation (17, 18) .
Fluorescence Microscopy and Image Analysis BEL-7402, BEL-7404, SMMC-7721, HepG2, and HL-7702 cells were all digested with 0.25% trypsin, suspended in serum-containing medium to 10 4 /mL, and grown on a 24-well chamber slide overnight. Cells were washed thrice with PBS and fixed with 4% paraformaldehyde before analysis in the next day. Subsequently, cells were incubated with 0.1 mg/mL FAM-labeled synthetic peptides (FAM-A54 and control peptide FAM-C10) for ∼1 h, and the cells were washed thrice with PBST-05 to elute unbound peptides. Fluorescence microscopy was done with an Olympus BX51TF microscope with a cooled frame charge-coupled device camera for FAM with excitation and emission wavelengths of 490 and 520 nm, respectively, and Image-Pro Plus 5.0 image analysis software.
Competition Binding Assay of Free Peptide A54
BEL-7402 cells were treated as above. After candidate cells have been fixed with 4% paraformaldehyde, they were severely washed and then treated with 1, 0.1, 0.01, and 0 mg/mL of unlabeled, chemically synthesized peptide A54 in different wells for ∼1 h. All these wells were also incubated with the 0.1 mg/mL FAM-labeled peptide A54 and washed following the same protocol as that used in Fluorescence Microscopy and Image Analysis.
Fluorescence-Activated Cell Sorting
BEL-7402, HL-7702, HCT-8, and HEK-293 cells were processed the same way as fluorescence microscopy analysis described above. Five different normal nude mouse tissues (heart, kidney, lung, liver, and spleen) were disaggregated by surgical instruments and trypsinized to get single-cell suspension. All cells were treated with 0.1 mg/mL FAM-A54 and FAM for 1 h at room temperature. After intensive washing by centrifugation to remove unbound fluorescein, fluorescence-activated cell sorting (FACS) analysis was conducted using a FACSCalibur flow cytometer (BD Biosciences) equipped with an argon laser set to excite samples at 488 nm and detect light emission at 530/35 nm. Mean fluorescence intensities were calculated using CellQuest software (19) .
In vitro Cytotoxicity Assay
For the MTT assay, the human liver tumor cells BEL-7402, BEL-7404, SMMC-7721, HepG2, and HL-7702 were all trypsinized and diluted to 10 5 /mL in RPMI 1640 with 10% FCS and then plated on a 96-well plate at 100 μL/well the day before use. The gradually diluted A54-DOX, A54M-DOX, and peptide A54 were added into the cells. Following 48 h of treatment, 10 μL MTT (1 mg/mL) was added to each well, and the plate was incubated for 4 h. All culture media were removed, and the cells were resuspended in 100 μL DMSO and incubated for 10 min. Cell viability was assessed by colorimetric change using a PowerWave XS Microplate spectrophotometer at 570 nm.
In vivo Antitumor Activity Assay
After tumors reached a volume of ∼1 cm At the same time, the body weight of each mouse was measured to evaluate the toxicity of these chemotherapeutic agents to the nude mouse. After 30 d of treatment, all mice were raised until they died. Survival data were plotted on Kaplan-Meier curve, and statistical calculations were done using the log-rank and χ 2 test where appropriate.
Statistical Analysis
Values are expressed as the mean ± SD. The significance of the difference from the respective controls for each experimental test condition was assayed by using Student's t test for each paired experiment. A P value of <0.01 or 0.001 was considered as statistically significant difference.
Results
In vivo Panning
Phages that specifically bind to tumor tissues were isolated and amplified by three rounds of in vivo panning. Both phage titers (Fig. 1A ) and recovery efficiency (Fig. 1B) were significantly improved after each round of panning. Approximately 80 phage clones were randomly picked out for sequencing analysis. As shown in Table 1 , no significant consensus sequence but a potential motif Pro-Se could be found among these phage clones.
Phage Binding Assay Using Cell-Based ELISA To confirm the specific binding of selected phages to BEL-7402, 130 independent phage clones were randomly picked out for testing by cell-based ELISA after the third round of in vivo panning. For calculating selectivity, the binding of each phage to BEL-7402 was compared with its binding to the control normal liver cell line HL-7702.
Phage clones A54, A67, and B2 seemed to have the most specific binding ability when compared with others (Fig. 1C) . From the DNA sequencing data (shown in Table 1), it was found that the peptide sequences TPRAELHFGQSS and AHQANFPSSSAI were displayed on phage clone B2 and A67, respectively.
In vivo Binding Assay
Two phage clones, A54 and C10 (HSYHSHSLLRMF, an irrelevant phage control), were chosen for further in vivo binding studies based on data obtained from sequencing and cell-based ELISA analyses. After direct injection of those two phages into nude mice for 15 minutes, the titer of phage in tumor and control tissues was determined. Their selectivity was assessed by the number of phages recovered in every gram of given tissue. The results presented in Fig. 2B pointed to a clear selectivity toward the tumor tissue for clone A54. Compared with other normal tissues, the amount of phages in tumor tissue was enhanced >20 times. In comparison, the irrelevant phage C10 distributed equally in almost every tissue, except brain. The tumor-targeting specificity of A54 was further confirmed by indirect immunohistochemical staining of bound phages in the tumor tissue in comparison with control normal tissues and Fig. 2A) . From the data shown in Fig. 2 , the tumor slices with phage A54 revealed significant binding compared with the irrelevant phage and control tissues.
Fluorescence Microscopy and Image Analysis
Because the selection and subsequent binding studies were all based on phage-displayed peptides, it is important to examine whether the same peptide can maintain the binding specificity when it is removed from the phage protein framework. The synthetic peptides A54 (AGKGTP-SLETTP) and C10 (HSYHSHSLLRMF) were labeled with a fluorescent (FAM) to the end of each peptide. Binding of the FAM-labeled A54 and C10 peptides to BEL-7402, BEL-7404, SMMC-7721, HepG2, and HL-7702 cells was examined using fluorescence microscopy. After intensive wash, fluorescent staining was observed on BEL-7402 (Fig. 3A) , BEL-7404, SMMC-7721, and HepG2 (Fig. 3B ) cells with FAM-labeled A54 but not on the control cell line HL-7702 (Fig. 3A) . However, when the FAMlabeled C10 was added to those cells, BEL-7402, HL-7702 (Fig. 3A) , BEL-7404, SMMC-7721, and HepG2 (Fig. 3B) could not display any visible fluorescence. The results clearly showed the specific binding ability of the peptide A54 to liver cancer cells in vitro.
Competition Binding Assay of Free Peptide A54
To justify the specific binding ability of free peptide A54, the unlabeled chemosynthetic peptide A54 was used to compete the binding of FAM-A54 with the BEL-7402 cell line. Along with the increase of free peptide, we can observe that the fluorescence intensity decreased distinctly (Fig. 3C) .
Fluorescence-Activated Cell Sorting
A total of eight different cells were examined to evaluate the specificity of FAM-labeled A54 by FACS. All of those cells were treated and tested in the same condition as that for BEL-7402. The FACS results were consistent with those obtained by cell-based ELISA and fluorescent microscopy analysis, indicating that A54 could bind to BEL-7402 specifically but not to other normal cell lines (Fig. 4A) . In addition, to ensure that fluorescence was not due to the inherent property of FAM, free FAM was included as a control and treated in the same way as the FAM-A54. None of those tested cell lines, including BEL-7402, showed any significant staining after treatment with free FAM.
In vitro Cytotoxicity Assay
The cytotoxic activity of the conjugate was determined by the MTT assay. The conjugate A54-DOX showed a potent and dose-dependent growth-inhibitory effect on several hepatocarcinoma cells, such as BEL-7402, BEL-7404, SMMC-7721, and HepG2. In contrast, only slight cytotoxicity of the A54-DOX was observed on normal liver cell HL-7702 under the same experimental conditions (Fig.  4B) , suggesting that, with the direction of peptide A54, the uptake of DOX by liver cancer cells was improved significantly when compared with the normal liver cells. Furthermore, the mutant peptide A54M with an altered motif Ala-Ala was also coupled to DOX to do the in vitro cytotoxic activity assay. The cytotoxicity of mutant A54M-DOX to the liver cancer cell line BEL-7402 was decreased when compared with A54-DOX (Fig. 4C) , suggesting that the potential motif Pro-Ser may play a very important role in binding to liver cancer cells. At the same time, we also treated BEL-7402 with unlabeled chemosynthetic peptide A54, but no visible cytotoxicity was found in A54-treated cells. Together, these data illustrate that the peptide A54 cannot inhibit the proliferation of BEL-7402 but only worked as a specific transport vector for DOX to liver cancer cells. The motif Pro-Ser may play a very important role in binding of A54 to liver cancer cells.
In vivo Antitumor Activity Assay
To determine whether the tumor-homing peptide A54 could be used to improve the therapeutic index of DOX, the DOX and A54 conjugates were used to treat mice bearing tumors derived from human hepatocarcinoma cell line BEL-7402. After the chemotherapeutics was injected, the growth of tumors was inhibited when compared with the group treated with D-Hank's and free DOX only (Fig.  5A) . At the same time, the body weights of mouse were measured to appraise the in vivo toxicity of DOX. There was no significant difference in body weight observed among the three groups, suggesting that the dosage of DOX is safe to mice (Fig. 5B) . Lastly, the long-term survival was extended by treatment with A54-DOX compared with untreated and DOX-treated mice. After the treatment, all mice that were treated with A54-DOX survived for >25 weeks. The entire D-Hank's buffer-treated and 60% DOX-treated mice died within the same time (Fig.  5C) , showing that the peptide A54 has potential application in liver cancer-targeting therapy. 
Discussion
One of the major challenges in improving cancer treatment and diagnostics is to develop a specific binding vector to cancer cells. Because cancer cells can often express particular cell surface antigens (tumor-associated antigens) in higher numbers, these antigens represent potential sites for delivery of toxic agents and become the mark of certain cancer. One of the major challenges of cancer treatment is to improve the accuracy and efficiency of targeting and diagnostics (20) . For this purpose, a small ligand that targets tumor tissues may greatly enhance both the precision of clinical diagnostics and the efficacy of drugs in cancertargeting therapy. Different avenues have been pursued to achieve this goal (21) . Among them, phage display approaches have shown great potential for isolating antibodies or peptides that recognize specific target molecules, such as vascular endothelial growth factor (22) , α v β 3 integrin (23, 24) , NF-κB (25) , and p53 (26, 27) . Many studies have shown that tissue-specific peptides can be isolated with no prior knowledge of the tissue profile by in vivo phage display technology (28, 29) . The homing peptides screened by in vivo phage display have revealed an unexpected degree of diversity of blood vessels (30) . The large number of tissues for which vascular homing peptides have already been found suggests that it will be possible to identify FIGURE 2. Specific binding assay of phage A54 in vivo. A, phage A54 or control phage C10 was injected into nude mice. After 15 min of circulation in the nude mouse, the distributions of A54 (a) and C10 (b) in tumor and A54 in control normal liver tissue (c) were assessed by immunohistochemistry. As an additional negative control, tumors in mice that were not injected with any phages (d) were also analyzed. Magnification, ×400. B, both phage clones A54 and C10 (negative control) are reinjected in the same way. Tumor, liver, and kidney tissues were reclaimed for phage titering. The phage number of each tissue in every gram was calculated by the titering result.
homing peptides that are selective for the given blood vessels in most, if not all, tissues. It is likely that additional homing peptides with specificity for tumor vasculature can also be found by screening various tumor cells (31, 32) .
Selection of phages on intact cells or in vivo as compared with selection using a defined protein reduces the probability of finding consensus sequences because the target protein is unknown and complicated, as shown in the current study. However, selection on defined/purified target molecules is not always applicable (e.g., for cell surface antigens in their native environment or in settings where the target antigen is unknown; ref. 33, 34) . Molecular events involved in tumorigenesis and metastasis, such as ligand binding, receptor dimerization, and activation of downstream pathways, have attracted a great deal of interests in recent years (35, 36) . The in vivo phage display technology has become a powerful tool for exploring these new frontiers. Ligands identified using this technology can also be used as a "warhead" of "biomissile" in tumor-targeting therapy (37, 38) . Several agents, such as cytotoxic or cytoprotective drugs (39) , gene therapy vectors (40) , or antigens, can be targeted to vascular endothelial cells in specific organs or tissues. Clinical trials to test targeted compounds are needed to translate this strategy into useful clinical applications.
In this study, we isolated phage clones from a random 12-mer linear peptide phage display library that bind to liver cancer tumor BEL-7402 by using in vivo panning. After three rounds of panning, ∼130 clones were selected randomly for further characterization. First, we used cell-based ELISA to confirm specific binding of phages to BEL-7402 cell line in vitro. The best-candidate phage A54 was selected for in vivo phage binding assay. The high ratio of phage recovered from tumor to that from control tissues further confirmed the selectivity of phage clone A54 in vivo. Next, we showed that the synthetic peptide FAM-A54 was able to maintain the binding specificity not only to BEL-7402 but also to BEL-7404, SMMC-7721, and HepG2 in vitro, proving that the binding specificity was determined by the peptide sequence alone without the involvement of flanking phage coat protein sequences. The unlabeled chemosynthetic peptide was chosen to compete the binding of FAM-A54, and the binding of FAM-A54 was blocked. Using FAM-A54, none of the eight nontumor cell lines tested showed any significant staining by using FACS, thus further confirming the binding specificity of A54 to liver cancer cells.
Analysis of amino acid sequences of peptide inserts from selected phage clones indicated that the overall sequence homology is limited, but the potential motif Pro-Ser could be detected in some of sequenced phages (Table 1) . Interestingly, similar consensus sequence was also detected from phage clones selected from the in vitro cell panning (i.e., direct panning on BEL-7402 cells in vitro; ref. 41) . This may indicate the presence of an abundant cell surface marker that is highly expressed both in vitro and in vivo. It will be interesting to see whether such cell surface markers can be identified and isolated using the A54 peptide as a selective reagent. To do more homology analyses on A54, peptide was searched for short, nearly exact match proteins using the National Center for Biotechnology Information BLAST against the NR database. Interestingly, homologies revealed some initial clues about the possible nature of the receptor(s). For example, the AGKGTPSLETTP sequence shows considerable homology with G protein-coupled receptor 112 and ITGA10 (α 10 integrin), which may play a pivotal role in angiogenesis and tumor metastasis (42, 43) , suggesting a potential relationship of the peptide A54 with cancer development and progression.
After the identification of specific binding ability to hepatocarcinoma, the peptide A54 and mutant peptide A54M was chemically synthesized and coupled to DOX to do the preliminary targeted therapy both in vitro and in vivo. When compared with normal liver cell line HL-7702, the tumor cell lines were killed distinctly by A54-DOX. But we still found that the proliferation of HL-7702 was also inhibited by A54-DOX, suggesting that, even if DOX has been directed by peptide A54, it still could be transported into cells nonspecifically by some mechanism. So it is also important to find a toxin that has been modified to delete nonspecific cell binding site to reduce the toxicity to normal cells at most. Now, we have established a truncated pseudomonas exotoxin A derivative that has a deletion of cell-binding domain to fuse with peptide A54, which could have potential application in liver tumor-targeting therapy in the future. Surprisingly, if the potential motif Pro-Ser in A54-DOX was mutated to Ala-Ala in A54M-DOX, the specific killing ability to liver cancer cells was restrained significantly in cytotoxicity assay. It would be very powerful evidence of Pro-Ser as the specific binding motif in peptide A54. It will also be a hint to us for further modification of A54 to optimize the in vivo binding ability.
DOX was first discovered in 1969 and soon became the most commonly used anticancer agent in clinical trials. However, the cytotoxic effect of DOX not only in the tumor cells but also in normal cells leads to severe side effects. Acute toxicity affects rapidly dividing cells, such as bone marrow cells and intestinal epithelial cells, and chronic toxicity affects more stable tissues, such as cardiac and 4 per well. The cell culture medium containing purified and gradually diluted immunotoxin was added to the cells the next day. Following 48 h of treatment, 10 μL MTT (1 mg/mL) was added to each well, and the plate was incubated for 4 h. All culture media were then removed, and the cells were resuspended in 100 μL DMSO and incubated for 10 min. Cell viability was assessed by colorimetric change using microplate spectrophotometer. C, BEL-7402 cells were treated as above and then the A54-DOX, A54M-DOX, and A54 were gradually diluted by culture medium and added to wells in the same way. After 48 h of treatment, cell viability was detected by MTT assay. *, P < 0.01; **, P < 0.001. hepatic tissues. This nonselective cytotoxicity is the main reason that limits the use of higher doses in most conventional chemotherapeutic drug regimens (44) . The commonly used dose of DOX in nude mice with human tumor xenografts is 50 to 200 μg/week (45) . To verify the specific delivery of DOX by A54 in vivo, we initially used the conjugates at a much lower dose of DOX equivalent to 20 μg/week. After 30 days of treatment, the tumor volume of A54-DOX-treated nude mouse was restrained compared with free DOX-treated and untreated groups, but, at the same time, the body weights among the three groups did not vary significantly, suggesting that the dosage of DOX is safe to mice. But with the help of the peptide A54, DOX accumulated efficaciously in the tumor tissues so only half of the common minimum dosage was enough to inhibit the proliferation of tumor cells. In conclusion, the present study showed that the peptide A54, which we screened by in vivo phage display technology, has the potential to be developed into a novel targeting therapy vector in DOX delivery.
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